Reduction of elevated IOP in patients w/ open angle glaucoma or ocular HTN as monotherapy in patients in whom topical β-blocker therapy is contraindicated or as adjunctive therapy to other IOP lowering medications when target IOP is not achieved w/ single agent.
Discontinue treatment if allergic reactions are observed. Delayed ocular hypersensitivity reactions. Patients w/ severe or unstable & uncontrolled CV disease; depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans. Dry eye patients & in those where cornea may be compromised. Remove contact lenses prior to application & wait at least 15 min before reinsertion. Avoid contact w/ soft contact lenses. Monitor patients in case of prolonged use. May impair ability to drive or operate machinery. Hepatic or renal impairment. Pregnancy. Not to be used during lactation. Not recommended in childn <12 yr. Closely monitor childn ≥2 yr (especially 2-7 yr weighing ≤20 kg) due to high incidence & severity of somnolence. Adolescents 12-17 yr.
S01GA07 - brimonidine ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants. S01EA05 - brimonidine ; Belongs to the class of sympathomimetics used in the treatment of glaucoma.
Sign Out
